Table 3.
Effect of antidrug antibodies (ADAs) on efficacy end points at week 12 in treatment‐emergent‐positive patients compared with negative and inconclusive (combined) patients
| Tildrakizumab treatment in part 1 | TE‐POS, N | Responders, n (%) | ADA‐NEG and inconclusive, N | Responders, n (%) |
|---|---|---|---|---|
| PASI 75 | ||||
| 100 mg | 30 | 18 (60.0) | 632 | 396 (62·7) |
| 200 mg | 29 | 20 (69.0) | 629 | 409 (65·0) |
| PASI 90 | ||||
| 100 mg | 30 | 11 (36.7) | 632 | 231 (36·6) |
| 200 mg | 29 | 9 (31.0) | 629 | 234 (37·2) |
| PASI 100 | ||||
| 100 mg | 30 | 3 (10.0) | 632 | 87 (13·8) |
| 200 mg | 29 | 3 (10.3) | 629 | 81 (12·9) |
| PGA ‘clear’ or ‘minimal’ | ||||
| 100 mg | 30 | 17 (56.7) | 632 | 364 (57·6) |
| 200 mg | 29 | 19 (65.5) | 629 | 378 (60·1) |
TE‐POS, treatment emergent ADA positive; NEG, negative; PASI, Psoriasis Area and Severity Index; PASI 75; ≥ 75% improvement in PASI; PGA, Physician's Global Assessment.